TranS1 targets $80.5m from IPO
This article was originally published in Clinica
Executive Summary
Minimally-invasive spinal surgery specialist TranS1 aims to raise $80.5m via flotation on the Nasdaq stock exchange. The Wilmington, North Carolina-based company, which filed for registration with the US Securities and Exchange Commission last week (July 24), plans to use the funds to further the development of its AxiaLIF (axial lumbar interbody fusion) product, as well as its disc replacement and prosthetic disc nucleus technologies. The company may also use some of the IPO proceeds to alleviate its financial shortcomings. TranS1 recorded a net loss of $9.5m for fiscal 2006, and in the first quarter of 2007, ending March 31, it lost $1.7m (an improvement of 7% on the same time period for the previous year).
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.